hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06378255, orgStudyIdInfo id: PKUSSNCT-23A04, secondaryIdInfos id: PKUSSIRB-202393160, type: OTHER, domain: Ethics Committee of PKUSH of Stomatology, secondaryIdInfos id: Z221100007422088, type: OTHER_GRANT, domain: The SFP for clinical CDTT in capital, briefTitle: Clinical Evaluation of Polycation-based New Dental Desensitizer on Dentin Hypersensitivity, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-20, primaryCompletionDateStruct date: 2025-06-30, completionDateStruct date: 2025-09-01, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Peking University Hospital of Stomatology, class: OTHER, descriptionModule briefSummary: Evaluate the safety and clinical efficacy of new dental desensitizers in the treatment of dentin sensitivity, including the relief of sensitivity symptoms and the duration of efficacy., conditionsModule conditions: Dentin Sensitivity, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Polycation-based new dentinal desensitizer, interventions name: GLUMA desensitizer, outcomesModule primaryOutcomes measure: Improvement of dentin sensitivity induced by probe pressure stimulation, secondaryOutcomes measure: Improvement of dentin sensitivity induced by air temperature stimulation, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Peking University School and Hospital of Stomatology, status: RECRUITING, city: Beijing, state: Beijing, zip: 100081, country: China, contacts name: Qianqian Wang, role: CONTACT, phone: +86-10-62173403, email: wangqian0213@163.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06378242, orgStudyIdInfo id: RC48-C029, briefTitle: To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-23, primaryCompletionDateStruct date: 2029-03-15, completionDateStruct date: 2029-12-31, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: RemeGen Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of intravesical instiliations of Disitamab Vedotin in patients with high-risk non-muscular invasive bladder cancer (NMIBC) that express HER2, conditionsModule conditions: High-risk Non-muscle Invasive Bladder Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: Disitamab Vedotin for injection, outcomesModule primaryOutcomes measure: Incidence of dose-limiting toxicity(DLT) (Phase I), primaryOutcomes measure: Incidence of Adverse event (Phase I), primaryOutcomes measure: Recommended Phase II Dose(RP2D), primaryOutcomes measure: Maximum Tolerated Dosage(MTD), secondaryOutcomes measure: Disease-free survival (DFS) rates, secondaryOutcomes measure: Duration of response (DOR), secondaryOutcomes measure: Disitamab Vedotin anti-drug antibody (ADA), secondaryOutcomes measure: PK of enfortumab vedotin: Maximum concentration (Cmax), secondaryOutcomes measure: PK of enfortumab vedotin: Trough concentration (Ctrough), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sun Yat-sen Memorial Hospital,SunYat-sen University, city: Guangzhou, state: Guangdong, country: China, contacts name: Tianxin Lin, Ph.D, role: CONTACT, geoPoint lat: 23.11667, lon: 113.25, locations facility: Hunan Cancer hospital, city: Changsha, state: Hunan, country: China, contacts name: Shusuan Jiang, M.D, role: CONTACT, geoPoint lat: 28.19874, lon: 112.97087, locations facility: The first affiliated hospital with nanjing medical universtity, city: Nanjing, state: Jiangsu, country: China, contacts name: qiang Lv, M.D, role: CONTACT, geoPoint lat: 32.06167, lon: 118.77778, locations facility: Shandong Cancer hospital & Institute, city: Jinan, state: Shangdong, country: China, contacts name: Jiasheng Bian, M.D, role: CONTACT, contacts name: Yuping Sun, role: SUB_INVESTIGATOR, geoPoint lat: 36.66833, lon: 116.99722, locations facility: The first affiliated hospital withXi'an Jiao Tong Universtity, city: Xi'an, state: Shanxi, country: China, contacts name: Lei Li, M.D, role: CONTACT, geoPoint lat: 34.25833, lon: 108.92861, hasResults: False
protocolSection identificationModule nctId: NCT06378229, orgStudyIdInfo id: ONZ-2023-0157, secondaryIdInfos id: 2022-501857-35-00, type: CTIS, briefTitle: Psilocybin for Hospitalized Patients With Treatment-resistant Depression, acronym: PSIHOS-D, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: University Hospital, Ghent, class: OTHER, collaborators name: Filament Health, descriptionModule briefSummary: The purpose of this study is to determine the safety and feasibility of performing psilocybin-assisted psychotherapy in patients hospitalized for treatment-resistant depression., conditionsModule conditions: Treatment Resistant Depression, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Open label feasibility study, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Psilocybin, outcomesModule primaryOutcomes measure: Incidence and type of Treatment-Emergent Adverse Events, primaryOutcomes measure: Columbia-Suicide Severity Rating Scale (C-SSRS), secondaryOutcomes measure: Recruitment and retention rates., secondaryOutcomes measure: Qualitative data from the semi-structured interviews with the subjects and their partners., otherOutcomes measure: Montgomery Asberg Depression Rating Scale (MADRS), otherOutcomes measure: Quick Inventory of Depressive Symptomatology - Self Rated (QIDS-SR), otherOutcomes measure: State-Trait Anxiety Inventory (STAI), otherOutcomes measure: World Health Organization Quality of Life Inventory-Brief subscale (WHOQOL-BREF), otherOutcomes measure: Maudsley 3-item Visual Analogue Scale (M3VAS), otherOutcomes measure: Subjective Emotional Health Visual Analogue Scale (SEHVAS), otherOutcomes measure: revised Dyadic Adjustment Scale (RDAS), otherOutcomes measure: Zarit Burden Interview - Short Form (Zarit-12 Burden Scale), otherOutcomes measure: Client Experiencing Scale (EXP), otherOutcomes measure: Mystical Experience Questionnaire (MEQ), otherOutcomes measure: Working Alliance Inventory - Short Revised (WAI-SR), otherOutcomes measure: Semi-structured interviews., otherOutcomes measure: EEG: sensor level analysis (power) and source level analysis (functional connectivity through amplitude envelope correlation), both in resting state and during an emotional paradigm., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ghent University Hospital, status: RECRUITING, city: Gent, state: Oost-Vlaanderen, zip: 9000, country: Belgium, contacts name: Cisse Geleyn, dr., role: CONTACT, phone: +3293328742, email: cisse.geleyn@uzgent.be, contacts name: Gilbert Lemmens, prof. dr., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 51.05, lon: 3.71667, hasResults: False
protocolSection identificationModule nctId: NCT06378203, orgStudyIdInfo id: MEDEA 1013, briefTitle: Rehabilitation in Muscular Dystrophies From the Hospital Facility to the Home: Pilot Project [RIMUDI], acronym: RIMUDI, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-15, primaryCompletionDateStruct date: 2024-12-15, completionDateStruct date: 2025-04-15, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: IRCCS Eugenio Medea, class: OTHER, descriptionModule briefSummary: Until twenty years ago physical exercise in muscular dystrophies was considered harmful to the muscle cells, inducing an acceleration of cell necrosis. In fact, it is now certain and validated that an active lifestyle and the practice of controlled and regular physical activity are to be considered therapeutic in neuromuscular pathologies with the aim of optimizing muscular and cardio-respiratory function and preventing atrophy In particular, it seems that the optimal care is extensive and can be carried out in a safe and controlled manner even at home.It is well documented that exercise has beneficial effects on muscle with increased strength and muscular endurance., conditionsModule conditions: Muscular Dystrophies, conditions: Limb Girdle Muscular Dystrophy, conditions: Facio-Scapulo-Humeral Dystrophy, conditions: Becker Muscular Dystrophy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Each patient will carry out a series of evaluation and training sessions (15 sessions) with a physiotherapist for the drafting of a personalized treatment plan which will subsequently be carried out "independently" at domicile.The home therapeutic proposal will include the use of the tele-rehabilitation system with virtual reality Home Kit - Virtual Reality Rehabilitation System (VRRS KHYMEIA) which allows to perform personalized games at home, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: tele-rehabilitation system with virtual reality Home Kit - Virtual Reality Rehabilitation System (VRRS KHYMEIA), outcomesModule primaryOutcomes measure: 6 minute walk test (6MWT), primaryOutcomes measure: Motor Function Measure scale (MFM), primaryOutcomes measure: Performance of Upper Limb (PUL), primaryOutcomes measure: Time up and go (TUG), secondaryOutcomes measure: Modification of fatigue and quality of life scales from T0 to T6, secondaryOutcomes measure: Short Form 36 (SF36), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Scientific Institute IRCCS Eugenio Medea, status: RECRUITING, city: Bosisio Parini, state: Lecco, zip: 23842, country: Italy, contacts name: Maria G D'Angelo, MD, role: CONTACT, phone: 031877111, phoneExt: +39, email: grazia.dangelo@lanostrafamiglia.it, geoPoint lat: 45.80075, lon: 9.29, hasResults: False
protocolSection identificationModule nctId: NCT06378164, orgStudyIdInfo id: P0041406, briefTitle: The Effect of Combined Volitional and Reactive Step Training in Reducing Falls Risk in Older Fallers, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-01, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2026-04, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: The Hong Kong Polytechnic University, class: OTHER, collaborators name: Chinese University of Hong Kong, collaborators name: Neuroscience Research Australia, collaborators name: The University of New South Wales, descriptionModule briefSummary: To examine the immediate and sustained effect of a 4-week combined volitional and reactive step training on fall risks in community-dwelling older fallers., conditionsModule conditions: Older Adults With a History of Falls, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 98, type: ESTIMATED, armsInterventionsModule interventions name: Exercise, interventions name: Active Control, outcomesModule primaryOutcomes measure: Choice Stepping Reaction Times, primaryOutcomes measure: Spring Scale Test, secondaryOutcomes measure: Mini Balance Evaluation System Test, secondaryOutcomes measure: Motor Control Test, secondaryOutcomes measure: Falls Efficacy Scale - International, secondaryOutcomes measure: Trail-Making Test, secondaryOutcomes measure: Programme Adherence, secondaryOutcomes measure: Prospective Falls, secondaryOutcomes measure: Adverse Events, eligibilityModule sex: ALL, minimumAge: 65 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Hong Kong Polytechnic University, status: RECRUITING, city: Hong Kong, country: Hong Kong, contacts name: Freddy Man Hin LAM, PhD, role: CONTACT, phone: 27666720, email: freddy-mh.lam@polyu.edu.hk, contacts name: Freddy Man Hin LAM, role: CONTACT, contacts name: Freddy Man Hin LAM, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 22.27832, lon: 114.17469, hasResults: False
protocolSection identificationModule nctId: NCT06378151, orgStudyIdInfo id: 2023P002243, briefTitle: Time-limited Trials in the Emergency Department, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-02-28, completionDateStruct date: 2025-09-30, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Brigham and Women's Hospital, class: OTHER, descriptionModule briefSummary: A randomized controlled trial of a structured conversation between clinicians and patients/surrogates to facilitate shared decision-making for intensive care use in seriously ill older adults being admitted to the intensive care unit from the emergency department., conditionsModule conditions: Emergencies, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Clinician-level randomization, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: TLT training, outcomesModule primaryOutcomes measure: Time to complete TLT conversations, primaryOutcomes measure: Patient-reported acceptability of TLT conversations, secondaryOutcomes measure: Intervention fidelity, secondaryOutcomes measure: Clinician-reported feasibility, secondaryOutcomes measure: Clinician-reported satisfaction, secondaryOutcomes measure: EHR documentation by inpatient clinicians, secondaryOutcomes measure: Heard and understood, secondaryOutcomes measure: Patient-reported end-of-life quality of communication, secondaryOutcomes measure: Decisional regret scale, secondaryOutcomes measure: The number of days to the first family meeting in ICU, secondaryOutcomes measure: ICU length of stay (LOS), secondaryOutcomes measure: Hospital LOS, secondaryOutcomes measure: The number of family meetings, secondaryOutcomes measure: ICU procedures (e.g., CPR, pressors, etc.), secondaryOutcomes measure: ICU mortality, secondaryOutcomes measure: Patterns of hospital disposition, secondaryOutcomes measure: Rate of hospice utilization, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Brigham and Women's Hospital, city: Boston, state: Massachusetts, zip: 02115, country: United States, geoPoint lat: 42.35843, lon: -71.05977, hasResults: False
protocolSection identificationModule nctId: NCT06378125, orgStudyIdInfo id: CIR-NA I, briefTitle: Evaluation of Safety and Pharmacokinetics of Oral Controlled-ileal-release Nicotinic Acid (CIR-NA) Compared to Immediate-release Nicotinic Acid and Placebo in Healthy Subjects and Subjects With Prediabetes, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-12-19, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-06-01, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: University Hospital Schleswig-Holstein, class: OTHER, descriptionModule briefSummary: A double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes., conditionsModule conditions: Safety Issues, conditions: Pharmacokinetic, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: OTHER, maskingInfo masking: DOUBLE, maskingDescription: Double (Participant, Investigator), whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: controlled-ileal-release nicotinic acid (SAD/ MAD/MD) single- and multiple-ascending dose (SAD/MAD) or multiple dose (MD), interventions name: immediate-release nicotinic acid (SAD), interventions name: Placebo controlled-ileal-release nicotinic acid (SAD/MAD), interventions name: Placebo immediate-release nicotinic acid (SAD), outcomesModule primaryOutcomes measure: Treatment-Emergent Adverse Events [Safety and Tolerability], primaryOutcomes measure: Treatment-Emergent Serious Adverse Events [Safety and Tolerability], primaryOutcomes measure: Haemoglobin, primaryOutcomes measure: White blood cells, primaryOutcomes measure: Blood creatinine, primaryOutcomes measure: Blood urea, primaryOutcomes measure: Blood uric acid, primaryOutcomes measure: Glomerular filtration rate, primaryOutcomes measure: Blood ALT, primaryOutcomes measure: Blood AST, primaryOutcomes measure: Blood GGT, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University Medical Center Schleswig-Holstein, Campus Kiel, status: RECRUITING, city: Kiel, state: Schleswig-Holstein, zip: 24105, country: Germany, contacts name: Corinna Geisler, PhD, role: CONTACT, phone: +4943150022243, email: studien.nutrisys.kiel@uksh.de, geoPoint lat: 54.32133, lon: 10.13489, hasResults: False
protocolSection identificationModule nctId: NCT06378099, orgStudyIdInfo id: InFaPro, briefTitle: Evaluation of the Effect of Consensual Pharmaceutical Indication Protocols for the Treatment of Minor Ailments, acronym: InFaPro, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08, primaryCompletionDateStruct date: 2025-02, completionDateStruct date: 2025-08, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Universidad de Antioquia, class: OTHER, collaborators name: Farmacias Pasteur, descriptionModule briefSummary: Minor ailments are non-serious, short-term health problems, not related to the patient's pathologies or to the desired or undesired effects of the medications they are taking. Pharmaceutical indication is the service provided in response to a patient's request, who comes to the pharmacy asking for a medication recommendation for a health problem; for this purpose, over-the-counter medications are used, which are pharmacological agents that can be acquired without a prescription. The practice of pharmaceutical indication turns self-medication into a safe and responsible practice, but it requires agreed-upon protocols., conditionsModule conditions: Community Pharmacy Services, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: An exploratory clinical trial with a baseline reference period of parallel groups will be conducted. The study will take place over a period of 10 months, during which 5 MA will be analyzed, and for each of them, patients will be followed up on days 3 to 5, and 7 to 10 post-care (intervention). Drugstores and drugstores/pharmacies (groups) will be randomized in a 1:1 ratio to enroll in the intervention group or the control group., primaryPurpose: OTHER, maskingInfo masking: NONE, maskingDescription: Blinding of the participants and the pharmacists involved in the care is not possible due to the nature of the intervention., enrollmentInfo count: 800, type: ESTIMATED, armsInterventionsModule interventions name: Patient guided and followed by the pharmacist, outcomesModule primaryOutcomes measure: Resolution time of the MA and the frequency of referral to a physician., secondaryOutcomes measure: Characterization of the population visiting drugstore or drugstore/pharmacy, secondaryOutcomes measure: Identification of the presence and classification of the MA, secondaryOutcomes measure: Need to acquire an OTC medication to treat the MA, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06378073, orgStudyIdInfo id: DPT/Batch-Fall19/557, briefTitle: Effects of Chest Physiotherapy Exercise in Prevention of Pre and Post Operative Complications By Cardiac Surgery, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-04-05, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-09-01, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Superior University, class: OTHER, descriptionModule briefSummary: "A randomized control trial will be conducted among 189 patients who have undergone cardiac surgery in past. The participants for this research will be patients of Pakistan Institute of Cardiology, University of Lahore Teaching Hospital, Azra Naheed Medical College and Bahria International Hospital. The chest physiotherapy technique will be applied on 2 controlled groups.In 94 patients the effects of chest physiotherapy will be checked post - operatively and the effects will be checked on other half pre - operatively. The data will be gathered on practical performance and treatment based along with questionnaire. The data collected will then be analyzed using SPSS", conditionsModule conditions: Surgery-Complications, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 189, type: ACTUAL, armsInterventionsModule interventions name: Incentive Spirometer, interventions name: Numeric Pain Rating Scale, outcomesModule primaryOutcomes measure: Incentive Spirometer, primaryOutcomes measure: Incentive Spirometer, eligibilityModule sex: ALL, minimumAge: 48 Years, maximumAge: 88 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Azra Naheed Medical College, Superior University, city: Lahore, state: Punjab, country: Pakistan, geoPoint lat: 31.558, lon: 74.35071, locations facility: Bahria Hospital, city: Lahore, state: Punjab, country: Pakistan, geoPoint lat: 31.558, lon: 74.35071, locations facility: Chaudary Muhammad Akram Teaching Hospital, Azra Naheed Medical College, Superior University, city: Lahore, state: Punjab, country: Pakistan, geoPoint lat: 31.558, lon: 74.35071, locations facility: The University of Lahore Teaching Hospital, city: Lahore, state: Punjab, country: Pakistan, geoPoint lat: 31.558, lon: 74.35071, locations facility: Punjab Institute of Cardiology Hospital, city: Lahore, country: Pakistan, geoPoint lat: 31.558, lon: 74.35071, hasResults: False